NovaGo Therapeutics
Founded 2015 · 10 employees on LinkedIn · 1 known investors
NovaGo Therapeutics is a Swiss biotech company developing human therapeutic antibodies that block the Nogo-A receptor to stimulate nerve growth and regeneration after spinal cord injury. Its antibody candidates aim to improve functional recovery in patients with spinal cord injury and have shown results in preclinical models, with Phase 1b clinical trials planned.
Investors · 1
Frequently asked questions
- What does NovaGo Therapeutics do?
- NovaGo Therapeutics is a Swiss biotech company developing human therapeutic antibodies that block the Nogo-A receptor to stimulate nerve growth and regeneration after spinal cord injury. Its antibody candidates aim to improve functional recovery in patients with spinal cord injury and have shown results in preclinical models, with Phase 1b clinical trials planned.
- Who are NovaGo Therapeutics's investors?
- NovaGo Therapeutics's investors include Pureos Bioventures.